NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Denali Therapeutics Inc. DNLI
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-2.97
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-45.7%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 10-year series below
Revenue
Net income
Per share
USD -2.97
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-45.7%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-40.7%
Each USD of equity lost 46 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.16B
Shares outstanding, FY2025
Change, 5 years+29.6%
Change, 10 years—
The share count grew 30% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.1B
total assets, end of FY2025
Total assetsUSD 1.1B
EquityUSD 1.0B
CashUSD 205.3M
Current ratio9.16×
Equity funds 89% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.0
0.0
0.3
0.1
0.0
0.3
0.0
0.1
0.0
0.0
Operating income $B
−0.6
−0.5
−0.2
−0.3
−0.3
0.1
−0.2
−0.0
−0.1
−0.1
EBITDA $B
−0.5
−0.5
−0.2
−0.3
−0.3
0.1
−0.2
−0.0
−0.1
−0.1
Income tax $B
0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
0.0
0.0
·
Net income $B
−0.5
−0.4
−0.1
−0.3
−0.3
0.1
−0.2
−0.0
−0.1
−0.1
EPS, diluted $
−2.97
−2.57
−1.06
−2.60
−2.39
0.63
−2.07
−0.39
−5.89
−13.49
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−45.7
−37.4
−14.0
−32.5
−27.5
9.2
−42.0
−7.2
−47.5
·
Shares out B
0.16
0.14
0.14
0.14
0.12
0.12
0.10
0.09
0.09
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
28 of 28
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed